Skip to main content

Proteomedix Partnering With Dynex on Automated Workflows for Prostate Cancer Test

NEW YORK ─ Swiss cancer diagnostics firm Proteomedix said today that it has formed a strategic partnership with lab automation company Dynex Technologies to develop automated workflows for Proteomedix's Proclarix prostate cancer test.

The partnership will allow Zurich-Schlieren-based Proteomedix to sell Proclarix in conjunction with the Dynex instrumentation on which the test was clinically validated.

Intended to aid diagnosis of clinically significant prostate cancer in patients with an elevated prostate-specific antigen score, Proclarix was validated on Dynex's DSX automated ELISA platform. The firms are working to make protocols for the test available for Dynex's DS2 and Agility platforms in the near future.

Dynex has an installed base of more than 7,500 instruments globally.

"Proteomedix and Dynex have worked together for a number of years during the development and clinical validation phase of Proclarix," ProteoMedix CEO Helge Lubenow said in a statement. "Now that we are directly selling and supporting Proclarix in conjunction with the Dynex automation systems, Proteomedix is well positioned to offer laboratory customers a single point of contact, full solution for their automated testing needs, improving the installation, training, and implementation process. With multiple instrument offerings customers can choose a 'right-sized' instrument that fits their needs."

"Partnering with Proteomedix aligns with our initiatives to drive growth of our core product line by leveraging partnerships to offer a growing menu of applications in the specialty oncology space," said Dynex CEO David Sholehvar.

Financial and other terms of the deal were not disclosed.